From innovation to commercialization
Willem de Laat
Managing Director
Life Sciences & Health
8 December 2010
From innovation to commercialization
Global biomedical trends
1 Trillion $ sales in 2014
150 billion $ patent expirations
Ongoing consolidation
75% diseases without cure
Healthy ageing
Strong R&D investment
• Ref.: Scrip News, April 2010
1. Roche - $8.7B2. Pfizer - $7.4B3. Novartis - $7.06B4. Johnson & Johnson - $6.66B5. Sanofi-Aventis - $6.25B6. GlaxoSmithKline - $5.59B7. Merck - $5.58B8. Takeda Pharmaceuticals - $4.64B
9. AstraZeneca - $4.23B 10. Eli Lilly - $4.13B11. Bristol-Myers Squibb - $3.48B12. Boehringer Ingelheim - $3.03B13. Abbott Laboratories - $2.61B14. Daiichi Sankyo - $1.89B15. Astellas Pharma - $1.63B
Global R&D spending
Health-related life sciences: an important sector in the Dutch economy
Drugs
Diagnostics
Devices
Companies Revenues FTE
Other
Total
Source: EIM study for EZ [2006], Voorstel LSG [2006]Preliminary data Biotech Outlook 2011
430
390
75
935
40
12.0 bn
2.7 bn
0.6 bn
15.7 bn
0.4 bn
37,000
12,000
54,600
3,400
± 150 companies highly innovative
Update 2010: >200 companies highly innovative
3% of GDP
2,200
The Dutch life sciences and health innovation cluster builds upon a strong knowledge base
Excellent biobanks and ‘real life’ datainfrastructure
120 mile radius
Global players & very high
concentration of SMEs
Excellentuniversities
5 of the top 10 European biotech deals are with Dutch companies, with a total value exceeding USD 2 billion
But....the consolidation changing environment has impact on the Netherlands
Organon Solvay Crucell
Life Sciences & Health Innovation ProgramImproving the investment and innovation climate in the Dutch life sciences and health sector
Hier komt een screenshot van de homepage 7 dec
5000+ unique visitors/month
Database forsubsidies and funding
Benchmark study on clinical trial performance to map the competitive
position of the Netherlands
Bio International Convention, Chicago, 2010
BIOBIO--EEUROPEUROPE SSPRINGPRING
MARCH 14-16, 2011, MARCH 14-16, 2011, MILAN, ITALYMILAN, ITALY
Thomson Pharma
Biotech Outlook 2011 will be launched in Q1 next year
Improved cluster assessment method • Cluster size, output & investments• Context with major events• Comparison with international clusters
Cooperation with international academicinstitutes
Cooperation on methodology with Council of European BioRegions
Progress
Sector vision
300 downloads
“TOPGEBIED LIFE SCIENCES”We have to Build, Nurture and Promote it together
Health &
Wealth
FEN-PHEN CASE (Wyeth)
Primary Pulmonary Hypertension on anti-obesity drug62 deaths before label change (1994)First court case (Billiton, Texas) $20 million20,000 claims < 1 monthDiscovery / browser /20,000 emailsWyeths prior knowledge exposedFirst settlement $1 billionReservations in Liability reserve fund total $21 billionStockprice decreased 50%
www.lifescienceshealth.com
Recommended
